BeiGene, Ltd.
06160
2022 3 31
13.09
571 XIVA
2022 3 31
2022 3 31
2022 2022
2023
2022 5 5
1
1995 (Private Securities Litigation
Reform Act of 1995)
10-K
2022 5 5
Anthony C. Hooper Margaret
Han Dugan Donald W. Glazer Michael Goller Ranjeev Krishana
Thomas Malley Alessandro Riva Corazon (Corsee) D. Sanders
2
2022
2022 2.616 1.061
146%
2022
372%
ALPINE
FDA EMA
RATIONALE306
2022 5 5
BGNE 06160 688235
2022
(John V. Oyler)
3
ALPINE
RATIONALE306
3
2022
2022 3 31 63
2021 12 31 66
2022 3 31 2.366
4.343 1.221
7,560 4,510 1,130
2022 3 31 3.066 2021
6.059
2022 3 31 2.616 2021
1.061
2022 1.043
2,210
2022
8,760
4,890
2022 2,990
1,450
2021 8 2022 1
2022
2,720 2,030
2022 3 31 4,510
2021
6.5 2021
3
2021 3 31 4.998
4
2022 3 31 7.499 2021
5.357
2022 3 31 6,520 2021
3,270
2021 8
2022 3 31 3.899 2021
3.207
CRO
2022 2021
0 850
2022 3 31
3,090 2021 2,190
(SG&A) 2022 3 31
SG&A 2.946 2021 SG&A 1.821
SG&A
SG&A
SG&A 2022 2021 SG&A
3,470 2,390
2022 3 31 4.343
6,650
2022 3 31 0.33
(ADS) 4.24 2021 3 31
0.06 0.05 ADS
0.73 0.69
5
2022 146%
2022
1.043 372%
6,790 570%
(MCL) (WM)
(MZL)
3,350 180%
(CLL)
2022
8,760 79%
(NRDL)
5
BTK
(BTK)
47
25
4,000
3 ALPINE(NCT03734016)
(IRC) (R/R) (CLL)
(SLL)
6
3 (NCT05100862)
R/R MZL
IgG4 PD-1
Fc γ
8
35 9,000
(MSI-H) (dMMR)
(ESCC)
(EMA)
ESCC (NSCLC)
NSCLC
NSCLC
EGFR ALK NSCLC
ESCC 3
RATIONALE306(NCT03783442)
(OS)
2022 (ASCO)
(NPC) 3 RATIONALE309(NCT03924986)
2022 ASCO
(AACR)2022
NSCLC 3 RATIONALE303(NCT03358875)
RATIONALE304(NCT03663205)
PD-L1>5% (G/GEJ) 3
RATIONALE305(NCT03777657)
7
(BGB-A1217) Fc TIGIT
25 1,000
o BGB-A445
OX40
o BGB-15025
1(HPK1)
o BGB-10188
PI3Kδ
o BGB-23339 2(TYK2)
BGB-16673 BTK CDAC B
1
BLINCYTO
(R/R)CD19 B
(ALL)
8
Zymeworks
Z y m e w o r k s
HERIZON-BTC-01(NCT04466891) Zanidatamab
HER2 (BTC)
III
IV
2022
100 9.3
5.2 6 2023
10
8,000 2022 GMP
64,000
(Ernst & Young
LLP)
2022 12 31
9
2021 (ESG)
ESG
2022 ASCO R/R 2
ROSEWOOD (NCT03332017)
WM 3 ASPEN (NCT03053440)
FDA CLL/SLL
(PDUFA) FDA 2022
10 22
EMA CLL MZL
2022 3 ALPINE(NCT03734016)
2022
(NMPA)
(NPC)
EMA
NSCLC ESCC (MAA)
2022 NPC
NSCLC
10
FDA ESCC
(BLA) PDUFA FDA
2022 7 12
2022
(HCC) 3
(NCT03412773)
(Ociperlimab)
2022
2022 1 (NCT04047862)
2022
3 (NCT03519230)
BGB-11417 BCL-2
2022
2022 (NHL)
CLL 1 NCT04277637 NCT04771130
2022 1
2022 BGB-A445(OX-40) 1
(NCT04215978)
2022 HPK1 BGB-15025
2022 LBL-007
surzebiclimab(TIM3) LBL-007 LAG-3
11
Zanidatamab
Zymeworks 2023 HERIZON-BTC-01(NCT04466891)
12
1,000
2022 2021
3 31 12 31
$ 6,252,233 $ 6,624,849
190,800 483,113
624,673 587,605
8,021,388 8,645,949
236,915 262,400
385,976 558,055
368,027 407,703
368,543 390,362
608,992 629,678
2,135,888 2,402,962
$ 5,885,500 $ 6,242,987
13
ADS ADS 1,000
3 31 3
2022 2021
$ 261,573 $ 106,117
45,053 499,755
306,626 605,872
65,237 32,685
389,915 320,726
294,573 182,106
188 188
749,913 535,705
(443,287) 70,167
10,071 (4,179)
11,967 (4,123)
(421,249) 61,865
13,025 (4,630)
(434,274) 66,495
$ (0.33) $ 0.06
$ (0.33) $ 0.05
1,332,017,262 1,188,943,726
1,332,017,262 1,257,489,671
ADS
$ (4.24) $ 0.73
$ (4.24) $ 0.69
ADS
102,462,866 91,457,210
102,462,866 96,729,975
14
40
2030 20
8,000
www.beigene.com.cn
1995 (Private Securities Litigation
Reform Act of 1995)
10-K
(+86 10)5895-8058 (+86 10)6844-5311
ir@beigene.com media@beigene.com
15
16